[{"orgOrder":0,"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Macrophage-based Therapeutics","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Macomics \/ Caribou Property Limited","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/ Caribou Property Limited"},{"orgOrder":0,"company":"Macomics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Macomics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Macomics","sponsor":"IFOM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Macrophage-targeted Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ IFOM","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ IFOM"},{"orgOrder":0,"company":"Macomics","sponsor":"Institute of Oncology Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Macrophage-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Macomics \/ Institute of Oncology Research","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Institute of Oncology Research"}]

Find Clinical Drug Pipeline Developments & Deals by Macomics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Macomics collaborates with the Institute of Oncology Research, focused on studying formulation and development through ENIGMAC macrophage drug discovery platform for the treatment of prostate cancer.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 19, 2024

                          Lead Product(s) : Macrophage-based Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Institute of Oncology Research

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration will combine advanced human ex vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 13, 2024

                          Lead Product(s) : Macrophage-targeted Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : IFOM

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest using its ENIGMACTM macrophage drug discovery platform.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 23, 2023

                          Lead Product(s) : Antibody

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. It is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 29, 2021

                          Lead Product(s) : Macrophage-based Therapeutics

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Caribou Property Limited

                          Deal Size : $5.8 million

                          Deal Type : Financing

                          blank